TolerogenixX GmbH develops a personalized cell therapy, MIC-Lx, which modifies donor-derived peripheral blood mononuclear cells to induce donor-specific immune tolerance in kidney transplant recipients. This approach significantly reduces the need for conventional immunosuppressive drugs, minimizing side effects and improving long-term graft survival rates.
Funding
$7.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Kidney transplant recipients face the challenge of long-term immunosuppression to prevent organ rejection, which can lead to significant side effects and increased risk of opportunistic infections. Current immunosuppressive drugs address the symptoms of rejection but do not tackle the underlying immune response, potentially compromising long-term graft survival.
Solution
TolerogenixX develops MIC-Lx, a personalized cell therapy designed to induce donor-specific immune tolerance in kidney transplant recipients, reducing or eliminating the need for conventional immunosuppression. The therapy involves modifying donor-derived peripheral blood mononuclear cells (PBMCs) using a proprietary MIC technology. The resulting MIC-Lx cell therapy is administered to the transplant recipient prior to transplantation, aiming to create a targeted and sustained immune tolerance. This approach addresses the root cause of immune responses, potentially leading to increased effectiveness, reduced side effects, and improved long-term outcomes for transplant recipients.
Target Audience
The primary target audience includes kidney transplant recipients and healthcare professionals involved in transplantation, as well as potential application in autoimmune disease.
Features
- Personalized cell therapy using donor-derived peripheral blood mononuclear cells (PBMCs).
- Proprietary MIC technology to modify PBMCs and induce donor-specific immune tolerance.
- Designed to reduce or eliminate the need for conventional immunosuppressive drugs.
- Aims to improve long-term graft survival rates and reduce side effects associated with immunosuppression.
- Demonstrated sustained safety and tolerability in Phase Ib clinical trials.
- Shown to maintain normal immune responses while suppressing unwanted immune reactions.
- Manufacturing process allows for scalable production and global availability.